Effects of α-lipoic acid and eicosapentaenoic acid in overweight and obese women during weight loss

Abstract

Objective: To evaluate the potential body weight-lowering effects of dietary supplementation with eicosapentaenoic acid (EPA) and a-lipoic acid separately or combined in healthy overweight/obese women following a hypocaloric diet. Methods: This is a short-term double-blind placebo-controlled study with parallel design that lasted 10 weeks. Of the randomized participants, 97 women received the allocated treatment [Control, EPA (1.3 g/ d), a-lipoic acid (0.3 g/d), and EPA 1 a-lipoic acid (1.3 g/d 1 0.3 g/d)], and 77 volunteers completed the study. All groups followed an energy-restricted diet of 30% less than total energy expenditure. Body weight, anthropometric measurements, body composition, resting energy expenditure, blood pressure, serum glucose, and insulin and lipid profile, as well as leptin and ghrelin levels, were assessed at baseline and after nutritional intervention. Results: Body weight loss was significantly higher (P < 0.05) in those groups supplemented with a-lipoic acid. EPA supplementation significantly attenuated (P < 0.001) the decrease in leptin levels that occurs during weight loss. Body weight loss improved lipid and glucose metabolism parameters but without significant differences between groups. Conclusions: The intervention suggests that a-lipoic acid supplementation alone or in combination with EPA may help to promote body weight loss in healthy overweight/obese women following energyrestricted diets.

Does alpha-lipoic acid supplement regulate blood pressure? A systematic review of randomized, double-blind placebo-controlled clinical trials

“…A significant reduction was observed within ALA group and between groups’ differences were significant for both SBP and DBP. In another study,[23] on healthy women, 0.3 g/day ALA for 10 weeks, made no significant difference between or within groups. In 2011, Koh et al .…”

Omega-3 fatty acids and adipose tissue function in obesity and metabolic syndrome

“…Indeed, n-3 PUFAs associated increases in leptin levels have been observed in obese subjects [135]. In this context, a recent study of our group has found that EPA supplementation (1300 mg/day, 10 weeks) prevents the fall of leptin during weight loss in overweight/obese women, suggesting that EPA could contribute to prevent weight regain in healthy weight-reduced subjects [136]. Taken together, these data highlight the relevance of the dose and duration of the treatment as well as the composition of the dietary fish oil and the metabolic state of the subjects on leptin production.…”

Essential role of Nrf2 in the protective effect of lipoic acid against lipoapoptosis in hepatocytes

“…In humans, clinical trials with LA in NAFLD have not been developed, but this is not the case of obesity, T2DM and associated complications [61]. We have recently reported that LA treatment increases mitochondrial biogenesis and promotes browning in subcutaneous adipocytes from overweight/obese subjects [62], as well as the beneficial effects of LA in promoting body weight loss in healthy overweight/obese women under energy-restricted diets [63]. Administration of LA to patients with T2DM decreased plasma oxidative products and improved insulin sensitivity [64], strengthening the potential of the antioxidant properties of LA in human therapeutics.…”